Geron Corporation (GERN)
Geron Corporation (GERN) Stock Price, Analysis & Data
| Bid | 1.39 |
| Market Cap | 1.02B |
| Revenue (ttm) | 204.56M |
| Net Income (ttm) | -67.61M |
| Beta | 0.59 |
| EPS (ttm) | -0.11 |
| PE Ratio (ttm) | n/a |
| Forward PE | 39.75 |
| P/B (ttm) | 4.45 |
| P/S (ttm) | 4.99 |
| Earnings Date | May 6, 2026 |
| Ask | 1.84 |
| Volume | 4,754,410 |
| Avg. Volume (20D) | 12,376,538 |
| Open | 1.63 |
| Previous Close | 1.63 |
| Day's Range | 1.58 - 1.64 |
| 52-Week Range | 1.04 - 2.01 |
| Analyst | Buy |
| Price Target | 4 (151.57%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About GERN
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is ...
Financial Performance
In 2025, Geron's revenue was 183.88M, an increase of 138.83% compared to the previous year's 76.99M. Earnings were -83.5M, a decrease of -52.17%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for GERN stock is "Buy". The 12-month stock price forecast is 4, which is upside of 151.57% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
